Skip to content

Randomized Controlled Study on the Hydrogel of Magnolia Flos Magnoliae Nanoparticle Extract for the Treatment of Allergic Rhinitis

Randomized Controlled Study on the Hydrogel of Magnolia Flos Magnoliae Nanoparticle Extract for the Treatment of Allergic Rhinitis

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099248
Enrollment
Unknown
Registered
2025-03-20
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Interventions

Mild control group:Hydrogel nasal drops: Shake the hydrogel well before use and apply 1-2 drops to each nostril 3-8 times a day for 14 days.
Mild test group:Xinyi flower nano extract hydrogel nasal treatment: Before use, shake well, drop 1-2 drops per nostril, use 3-8 times a day for 14 consecutive days.

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Two or more symptoms, such as paroxysmal sneezing, watery nose, nasal itching and nasal congestion, persist or accumulate for more than 1 hour per day (quality of life (including sleep, daily life, work and study have no significant impact); 2.The signs were pale and swollen nasal mucosa, edema of inferior turbinate and watery secretion of nasal cavity; 3.Age 18-85 years old; 4. Voluntarily participate in this study and be able to cooperate with the follow-up work of this study, and be able to understand and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Does not meet the above inclusion criteria; 2. A known history of allergy to the investigational agent or any of its related ingredients; 3. Participate in other clinical trials within the past 1 month; 4. Patients with sinusitis, drug-induced rhinitis, and nasal polyps; 5. Serious primary diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system.

Design outcomes

Primary

MeasureTime frame
total nasal symptom score;

Secondary

MeasureTime frame
Quality of life scores;total non-nasal symptom score;

Countries

China

Contacts

Public ContactZhanqi Tong

Chinese PLA General Hospital

tong.zhanqi@163.com+86 188 1053 6167

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026